


**CLAIMS:**

1. A compound of formula I:



5

or a pharmaceutically acceptable salt thereof wherein:

Ar is phenyl, benzisothiazol-3-yl or benzthiophen-3-yl, each of which bears substituent groups R¹, R² and R³;

10 R¹ is hydrogen, fluorine, chlorine, bromine, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkoxy, C<sub>2-6</sub> alkenyloxy, C<sub>2-6</sub> alkynyloxy, or C<sub>1-6</sub> alkyl substituted by up to 5-fluorine atoms;

R² is hydrogen, fluorine, chlorine, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl substituted by up to 5 fluorine atoms or C<sub>1-4</sub> alkoxy substituted by up to 5 fluorine atoms;

15 R³ is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

Q¹ is hydrogen; fluorine; chlorine; bromine; C<sub>1-6</sub> alkyl; C<sub>3-6</sub> cycloalkyl; C<sub>2-6</sub> alkenyl; C<sub>2-6</sub> alkynyl; C<sub>1-6</sub> alkoxy; C<sub>2-6</sub> alkenyloxy; C<sub>2-6</sub> alkynyloxy; C<sub>1-6</sub> alkyl substituted by up to 5-fluorine atoms; nitrile; COQ⁴ or CO<sub>2</sub>Q⁴ where Q⁴ is hydrogen or C<sub>1-6</sub> alkyl; NQ⁵Q⁶, CONQ⁵Q⁶ or SO<sub>2</sub>NQ⁵Q⁶ where Q⁵ is hydrogen or C<sub>1-6</sub> alkyl and Q⁶ is hydrogen or C<sub>1-6</sub> alkyl or Q⁵ and Q⁶ are joined to form either a 4-7 membered heterocyclic ring which may also contain one oxygen or one further nitrogen ring atom, which heterocyclic ring may optionally be substituted by up to 3 fluorine atoms or by CF<sub>3</sub>, methyl, ethyl or hydroxyl; hydroxyl; nitro; SOQ⁷ or SO<sub>2</sub>Q⁷ where Q⁷ is C<sub>1-4</sub> alkyl; NQ⁸COQ⁹, NQ⁸CO<sub>2</sub>Q⁹ or NQ⁸SO<sub>2</sub>Q⁹ where Q⁸ is hydrogen or C<sub>1-4</sub> alkyl and Q⁹ is hydrogen or C<sub>1-4</sub> alkyl or is joined to Q⁸ to form a 5-7 membered ring; a heteroaromatic ring of 5 ring atoms 1, 2, 3 or 4 of which may be nitrogen atoms or 1 or 2 of which are nitrogen atoms and 1 of which is an oxygen or sulfur atom or 1 of

- 30 -

which is an oxygen or sulfur atom, which heteroaromatic ring optionally being substituted by methyl, ethyl or hydroxyl; or a heteroaromatic ring of 6 ring atoms containing 1 or 2 nitrogen ring atoms or a phenyl group either of which is optionally substituted by 1 or 2 fluorine or chlorine atoms or C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy or trifluoromethyl groups;

5 Q<sup>2</sup> is hydrogen, fluorine, chlorine, nitrile, hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl substituted by up to 5 fluorine atoms, or C<sub>1-4</sub> alkoxy substituted by up to 5 fluorine atoms;

10 Q<sup>3</sup> is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

or Q<sup>2</sup> and Q<sup>3</sup> are joined to form the residue of a 5, 6 or 7 membered carbocyclic ring;

R<sup>4</sup> is H or C<sub>1-4</sub> alkyl,

m is 0 or 1;


15 n is 0, 1 or 2; and

W is CH<sub>2</sub>, CHF, CH(OH) or CO.

2. A compound according to claim 1 wherein Ar represents benzisothiazol-3-yl or benzthiophen-3-yl, each bearing substituent groups R<sup>1</sup>, R<sup>2</sup> and 20 R<sup>3</sup>, and m and n are both 0.

3. A compound according to claim 1 wherein Ar represents phenyl bearing substituent groups R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>, m is 1 and n is 0.

25 4. A compound according to claim 1 of formula IIA:



(IIA)

- 31 -

or a pharmaceutically acceptable salt thereof;

wherein R<sup>13</sup> represents H and R<sup>14</sup> represents H, F or OH, or R<sup>13</sup> and R<sup>14</sup> together represent keto;

and Q<sup>1</sup>, Q<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup> and R<sup>4</sup> are as defined in claim 1.

5

5. A compound according to any previous claim wherein Q<sup>1</sup> is selected from H, F, Cl, Br, CN, carboxamide, 5-membered heteroaryl and NQ<sup>5</sup>Q<sup>6</sup> where Q<sup>5</sup> and Q<sup>6</sup> complete a heterocyclic ring;

Q<sup>2</sup> is H, F or Cl;

10

Q<sup>3</sup> is H or F;

R<sup>1</sup> is H, F, methyl or CF<sub>3</sub>;

R<sup>2</sup> is H, F, methyl or CF<sub>3</sub>; and

R<sup>3</sup> is H.

15

6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

7. A compound according to claim 1 for use in a method of treatment of the human body.

20

8. The use of a compound according to claim 1 for the manufacture of a medicament for treating or preventing a condition mediated by 5-HT<sub>2A</sub> receptor activity.

25

9. A method of treatment of a subject suffering from or prone to a condition mediated by 5-HT<sub>2A</sub> receptor activity which comprises administering to that subject an effective amount of a compound according to claim 1.

30